头孢他啶阿维巴坦药物利用评价标准的建立与应用  

Establishment and application of drug use evaluation criteria for ceftazidime-avibactam

作　　者：冀建伟[1] 李桃英[1] 李志业[1] 焦红军[1] JI Jian-wei;LI Tao-ying;LI Zhi-ye;JIAO Hong-jun(Department of Pharmacy,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China)

机构地区：[1]郑州大学第二附属医院药学部,郑州450014

出　　处：《医药论坛杂志》2020年第10期66-69,共4页Journal of Medical Forum

摘　　要：目的建立头孢他啶阿维巴坦药物利用评价标准,评价头孢他啶阿维巴坦临床应用的合理性,规范头孢他啶阿维巴坦的临床应用。方法依照美国医院药师协会制定的药物利用评价方法,采用专家咨询法制定《头孢他啶阿维巴坦DUE标准》,对2019年11月—2020年6月郑州大学第二附属医院所有使用头孢他啶阿维巴坦的出院病历进行分析。结果 12例病历中,7例完全符合评价标准,占58.3%。其中用药指征、用药过程、用药结果、用药管理符合标准率分别为100%、75%、75%、91.7%。头孢他啶阿维巴坦临床应用中用药过程存在问题最多,分别为用法用量不适宜2例次(16.7%)、联合用药不适宜2例次(16.7%)、疗程不适宜1例次(8.3%)。结论头孢他啶阿维巴坦临床用药过程中存在一定问题,主要为用药过程方面,建立的《头孢他啶阿维巴坦DUE评价标准》能够评价头孢他啶阿维巴坦临床用药的全过程,可规范头孢他啶阿维巴坦的临床使用。Objective To establish the drug use evaluation criteria of ceftazidime-avibactam(CAZ-AVI) and standardize the rational use of CAZ-AVI.Methods According to Drug Use Evaluation(DUE), the DUE criteria of CAZ-AVI was formulated by expert consultation method. 12 hospitalized patients in Second Affiliated Hospital of Zhengzhou University who was used CAZ-AVI from November 2019 to June 2020 was included.Results Among the 12 cases, 7 cases(58.3%) completely reached the evaluation criteria. The coincidence rate of medication indication, medication process, medication results, medication management were 100%, 75%, 75%, 91.7% respectively. The maximum problems were in medication process of CAZ-AVI clinical practice: 2 cases(16.7%) were inappropriate usage and dosage, 2 cases(16.7%) were inappropriate combination therapy, and unsuitable course of treatment in 1 case(8.3%).Conclusion There are some inappropriate medication problems in utilization of CAZ-AVI, mainly in the aspects of medication process. Established the "DUE for CAZ-AVI " can standardize the clinical utilization of CAZ-AVI.

关 键 词：头孢他啶阿维巴坦 药物利用评价 药物利用评价标准 

分 类 号：R954[医药卫生—药学]